A new test may reveal which patients will respond to treatment for graft versus host disease , an often life-threatening complication of stem cell transplants used to treat leukemia and other blood disorders, according to a study. A new test may reveal which patients will respond to treatment for graft versus host disease , an often life-threatening complication of stem cell transplants used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.
http://ift.tt/1AFeojG
http://ift.tt/1AFeojG
No comments:
Post a Comment